Patents by Inventor Halina Offner
Halina Offner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11945855Abstract: Recombinant polypeptides comprising a modified DR?1 domain are provided. In some embodiments, the polypeptides include the modified DR?1 domain, an antigenic peptide, and optionally a linker sequence. Pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said recombinant polypeptides or pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides are also provided.Type: GrantFiled: October 4, 2019Date of Patent: April 2, 2024Assignees: Oregon Health & Science University, The United States Government as represented by the Department of Veterans AffairsInventors: Roberto Meza-Romero, Arthur A. Vandenbark, Halina Offner
-
Publication number: 20210380660Abstract: Recombinant polypeptides comprising a modified DR?1 domain are provided. In some embodiments, the polypeptides include the modified DR?1 domain, an antigenic peptide, and optionally a linker sequence. Pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said recombinant polypeptides or pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides are also provided.Type: ApplicationFiled: October 4, 2019Publication date: December 9, 2021Applicants: Oregon Health & Science University, The United States Government as represented by the Department of Veterans AffairsInventors: Roberto Meza-Romero, Arthur A. Vandenbark, Halina Offner
-
Patent number: 10137177Abstract: Methods of treating neuroinflammation by administration of a selective protein C activator, such as recombinant human WE thrombin and optionally one or more of its cofactors are disclosed. Also disclosed are pharmaceutical compositions for use in the treatment of mammals that exhibit symptoms of neurological inflammation. The pharmaceutical compositions and pharmacological dose comprise a safe and effective amount of WE thrombin.Type: GrantFiled: January 21, 2015Date of Patent: November 27, 2018Assignees: Oregon Health & Science University, The United States of America as respresented by the Department of Veterans AffairsInventors: Owen J. McCarty, Norah Verbout, Halina Offner-Vandenbark, Erik I. Tucker
-
Publication number: 20180271935Abstract: Methods and compositions used in treating traumatic brain injury using a recombinant DR?-MOG-35-55 construct are disclosed. The disclosed methods involve administering a pharmaceutical composition comprising DR?-MOG-35-55 and a pharmaceutically acceptable carrier to a subject that has had a traumatic brain injury.Type: ApplicationFiled: March 14, 2018Publication date: September 27, 2018Applicant: OREGON HEALTH & SCIENCE UNIVERSITYInventors: Halina Offner, Arthur Vandenbark
-
Publication number: 20170007681Abstract: Methods of treating neuroinflammation by administration of a selective protein C activator, such as recombinant human WE thrombin and optionally one or more of its cofactors are disclosed. Also disclosed are pharmaceutical compositions for use in the treatment of mammals that exhibit symptoms of neurological inflammation. The pharmaceutical compositions and pharmacological dose comprise a safe and effective amount of WE thrombin.Type: ApplicationFiled: January 21, 2015Publication date: January 12, 2017Applicants: Oregon Health & Science University, The United States Government as represented by the Department of Veterans AffairsInventors: Owen J. McCarty, Norah Verbout, Halina Offner-Vandenbark, Erik I. Tucker
-
Patent number: 9492536Abstract: Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked ?1 and ?1 domains, and MHC class I-based molecules that comprise covalently linked ?1 and ?2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, including treatment and/or prevention of central nervous system damage relating to stroke.Type: GrantFiled: June 5, 2015Date of Patent: November 15, 2016Assignees: Oregon Health & Science University, The United States of America as represented by the Department of Veterans AffairsInventors: Halina Offner, Patricia D. Hurn, Arthur A. Vandenbark, Gregory G. Burrows
-
Publication number: 20150343055Abstract: Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked ?1 and ?1 domains, and MHC class I-based molecules that comprise covalently linked ?1 and ?2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, including treatment and/or prevention of central nervous system damage relating to stroke.Type: ApplicationFiled: June 5, 2015Publication date: December 3, 2015Inventors: Halina Offner, Patricia D. Hurn, Arthur A. Vandenbark, Gregory G. Burrows
-
Patent number: 9050279Abstract: Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked ?1 and ?1 domains, and MHC class I-based molecules that comprise covalently linked ?1 and ?2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, including treatment and/or prevention of central nervous system damage relating to stroke.Type: GrantFiled: June 21, 2013Date of Patent: June 9, 2015Assignees: Oregon Health & Science University, The United States of America as represented by the Department of Veterans AffairsInventors: Halina Offner, Patricia D. Hurn, Arthur A. Vandenbark, Gregory G. Burrows
-
Publication number: 20150099706Abstract: Methods and compositions used in treating ischemic stroke using a recombinant DR?-MOG-35-55 construct are disclosed. The disclosed methods involve administering a pharmaceutical composition comprising DR?-MOG-35-55 and a pharmaceutically acceptable carrier to a subject that has had or is at risk of developing ischemic stroke.Type: ApplicationFiled: October 3, 2014Publication date: April 9, 2015Inventors: Halina Offner-Vandenbark, Nabil Alkayed, Arthur A. Vandenbark
-
Publication number: 20140056936Abstract: Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked ?1 and ?1 domains, and MHC class I-based molecules that comprise covalently linked ?1 and ?2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, including treatment and/or prevention of central nervous system damage relating to stroke.Type: ApplicationFiled: June 21, 2013Publication date: February 27, 2014Applicants: The United States Government as represented by the Department of Veterans Affairs, Oregon Health & Science UniversityInventors: Halina Offner, Patricia D. Hurn, Arthur A. Vandenbark, Gregory G. Burrows
-
Publication number: 20130316338Abstract: Disclosed are methods used to diagnose Alzheimer's disease (AD) in a subject. The methods involve determining the amount of chemokine receptor 6 (CCR6) expressed in a biological sample. Expression of CCR6 in the sample that exceeds a threshold level of expression signifies that the subject has AD, even if the subject has not yet developed symptoms of AD. The methods may also be used to monitor the effectiveness of an AD treatment. Kits that facilitate the use of the methods are also disclosed.Type: ApplicationFiled: June 28, 2011Publication date: November 28, 2013Applicants: The United States Government as Represented by the Department of Veterans Affairs, Oregon Health & Science UniversityInventors: Halina Offner-Vandenbark, Joseph F. Quinn, Sandhya Subramanian
-
Patent number: 8491913Abstract: Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked ?1 and ?1 domains, and MHC class I-based molecules that comprise covalently linked ?1 and ?2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, including treatment and/or prevention of central nervous system damage relating to stroke.Type: GrantFiled: March 8, 2010Date of Patent: July 23, 2013Assignees: Oregon Health & Science University, The United States of America as represented by the Department of Veterans AffairsInventors: Halina Offner, Arthur A. Vandenbark, Gregory G. Burrows, Patricia D. Hurn
-
Patent number: 8053197Abstract: The present disclosure relates to methods for inhibiting an autoimmune disease by administering to a subject a therapeutically effective amount of a composition that increases FOXP3 expression, thereby inhibiting the autoimmune disease. Further disclosed herein are methods for detecting in a subject an autoimmune disease or a predisposition to an autoimmune disease, and methods for assessing the efficacy of a therapy for an autoimmune disease.Type: GrantFiled: July 29, 2005Date of Patent: November 8, 2011Assignees: Oregon Health & Science University, The United States of America as represented by the Department of Veterans AffairsInventors: Arthur A. Vandenbark, Halina Offner, Richard Bartholomew
-
Publication number: 20110217308Abstract: Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked ?1 and ?1 domains, and MHC class I-based molecules that comprise covalently linked ?1 and ?2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, including treatment and/or prevention of central nervous system damage relating to stroke.Type: ApplicationFiled: March 8, 2010Publication date: September 8, 2011Inventors: Halina Offner, Arthur A. Vandenbark, Gregory G. Burrows, Patricia D. Hurn
-
Publication number: 20110124614Abstract: Methods and compositions are provided which confer protection against autoimmune diseases without triggering intracellular estrogen receptors. Such methods and compositions limit the side effects of steroids while providing the benefits conferred by such medications through the activation of membrane estrogen receptors.Type: ApplicationFiled: May 13, 2010Publication date: May 26, 2011Inventors: HALINA OFFNER, CHUNHE WANG, BABAK DEHGHANI
-
Patent number: 7731973Abstract: The invention provides a method of ameliorating a Th1-mediated immune pathology in a mammal. The method is practiced by administering a low dose of estrogen to the mammal. Optionally, an immunotherapeutic agent can also be administered to the mammal. Also provided are kits containing a low dose of estrogen and an immunotherapeutic agent.Type: GrantFiled: April 15, 2008Date of Patent: June 8, 2010Assignees: Oregon Health and Science University, The United States of America as represented by the Department of Veterans AffairsInventor: Halina Offner
-
Publication number: 20090280135Abstract: Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked ?1 and ?1 domains, and MHC class I-based molecules that comprise covalently linked ?1 and ?2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, to treat or prevent autoimmune or neurodegenerative diseases, to protect axons, and to prevent or reverse demyelination.Type: ApplicationFiled: June 6, 2007Publication date: November 12, 2009Inventors: Halina Offner, Arthur Vandenbark, Gregory G. Burrows
-
Patent number: 7579006Abstract: The invention provides a method of ameliorating a Th1-mediated immune pathology in a mammal. The method is practiced by administering a low dose of estrogen to the mammal. Optionally, an immunotherapeutic agent can also be administered to the mammal. Also provided are kits containing a low dose of estrogen and an immunotherapeutic agent.Type: GrantFiled: April 3, 2008Date of Patent: August 25, 2009Assignees: Oregon Health and Science University, The United States of America as represented by the Department of Veterans AffairInventor: Halina Offner
-
Publication number: 20090010885Abstract: The present disclosure relates to methods for inhibiting an autoimmune disease by administering to a subject a therapeutically effective amount of a composition that increases FOXP3 expression, thereby inhibiting the autoimmune disease. Further disclosed herein are methods for detecting in a subject an autoimmune disease or a predisposition to an autoimmune disease, and methods for assessing the efficacy of a therapy for an autoimmune disease.Type: ApplicationFiled: July 29, 2005Publication date: January 8, 2009Inventors: Arthur A. Vandenbark, Halina Offner, Richard Bartholomew
-
Publication number: 20080227761Abstract: The invention provides a method of ameliorating a Th1-mediated immune pathology in a mammal. The method is practiced by administering a low dose of estrogen to the mammal. Optionally, an immunotherapeutic agent can also be administered to the mammal. Also provided are kits containing a low dose of estrogen and an immunotherapeutic agent.Type: ApplicationFiled: April 3, 2008Publication date: September 18, 2008Inventor: Halina Offner